Editorial Review
AIDS 2019, 33:1411–1420
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is ...occupational exposure to the disease
more
A Summary
Accessed: 23.11.2019
Endorsed by the CCM Georgia on April 15th 2015
Accessed: 26.09.2019
Country Progress Report
Reporting Period
January – December, 2014
Accessed: 26.09.2019
The following protocol has been designed to investigate the First Few X cases (FFX) and their close contacts. It is envisioned that the FFX 2019-nCoV investigation will be conducted across several countries or sites with geographical and demographical diversity. Using a standardized protocol such a...s the protocol provided here, epidemiological exposure data and biological samples can be systematically collected and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally for timely estimates of 2019-nCoV infection severity and transmissibility, as well as to inform public health responses and policy decisions. This is particularly important in the context of a novel respiratory pathogen, such as 2019-nCoV
more
Outline
• Welcome and objectives
• Microbiology, epidemiology and clinical presentation
• Surveillance for imported cases including case definitions
• Laboratory diagnosis • Infection prevention and hospital readiness
• Patient flow and actions required at each step
• Co-ord...inating a public health response
more
This document provides guidance to EU/EEA Member States on environmental cleaning in healthcare and non-healthcare settings during the COVID-19 pandemic.
Last update: 2 April 2020
Thematic Report– 3 April 2020
ACAPS Risk Analysis: COVID19
info@acaps.org
The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more